Wcn26-6463 Safety and Preliminary Efficacy Findings From a Phase 2a Randomized, Double-blind, Placebo-controlled Trial of Setanaxib in Patients With Alport Syndrome
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Alport syndrome is a rare genetic disease resulting from collagen IV abnormalities and is marked by interstitial fibrosis and declining kidney function. Fibrosis prevention may preserve kidney function. We report safety and preliminary efficacy findings with setanaxib, an enzyme-driven hydrogen peroxide-depleting agent with anti-fibrotic properties, in patients with Alport syndrome.
Source: Kidney International Reports
Institutions: University College London, Vall d'Hebron Institut de Recerca, Great Ormond Street Hospital, Instituto de Investigación Biosanitaria de Granada, Hospital Universitario Virgen de las Nieves, Nottingham University Hospitals NHS Trust, University Hospital Olomouc, Palacký University Olomouc, Hospital Universitario 12 De Octubre, Charles University, University Hospital Hradec Králové, General University Hospital in Prague, Universitat Autònoma de Barcelona, Puigvert Foundation, Institut de Recerca Sant Pau, Institute of Clinical and Experimental Medicine, Calliditas Therapeutics AB (Sweden), Royal Manchester Children's Hospital
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
OpenAlex ID: W7140307190